After MI, de-escalating ticagrelor to clopidogrel benefits under-75s; older adults less certain

Design

Prespecified secondary analysis of the TALOS-AMI randomised trial, by age

Population

2,697 patients stabilised one month after PCI for myocardial infarction

Primary outcome

Net clinical endpoint (ischaemic events plus BARC 2/3/5 bleeding) at 1 year

Effect

<75: 4.1% vs 7.2% (hazard ratio 0.54, 0.38–0.77); ≥75: 6.4% vs 11.6% (0.54, 0.25–1.17, non-significant)

Potent antiplatelets prevent ischaemic events but drive bleeding, a trade-off that worsens with age. This prespecified analysis of TALOS-AMI asked whether switching from ticagrelor to clopidogrel a month after PCI works differently by age, in 2,697 stabilised, event-free patients.

In patients under 75, de-escalation clearly helped: the net clinical endpoint fell from 7.2% to 4.1% (adjusted hazard ratio 0.54) and bleeding from 4.9% to 2.8% (0.54). In those 75 and over the point estimates pointed the same way — fewer events and much less bleeding — but with far fewer patients the confidence intervals crossed one, so the benefit was not statistically confirmed. There was no statistical age interaction.

The practical reading: for a stabilised patient under 75 after MI, planned de-escalation to clopidogrel at about a month is a sound way to cut bleeding without losing ischaemic protection. In those 75 and over — the group with the most to gain from less bleeding — the same approach is reasonable to consider but remains unproven, so individualise it to bleeding and ischaemic risk, and watch the first six months when most bleeding occurred.

• Under 75, de-escalation cut the net clinical endpoint (4.1% vs 7.2%; adjusted hazard ratio 0.54, 0.38–0.77) and bleeding (2.8% vs 4.9%; 0.54, 0.35–0.82).
• At 75 and over, point estimates matched but were not significant (primary 6.4% vs 11.6%; bleeding 3.2% vs 7.9%), with wide intervals.
• There was no statistical interaction by age, so the lack of significance in elders reflects few events, not a different effect.
• Consider planned de-escalation to clopidogrel at about one month after MI; individualise in the over-75s and watch the first 6 months for bleeding.

Why it matters

It supports a concrete deprescribing step after MI and is honest that the group who could gain most, the oldest, is the least tested.

Don't overread it

The over-75 subgroup was small with wide confidence intervals — this does not establish de-escalation is beneficial or safe in the oldest patients.

The statistics, in plain English

A hazard ratio of 0.54 means roughly half the events; under 75 the intervals stayed below 1, so the benefit is firm, while in the over-75s the identical point estimate had intervals crossing 1 because there were too few patients — uncertainty, not absence of benefit.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.